Patent · US Active

Antibody fusion proteins with a modified FcRn binding site

US8907066B2 · kind B2 · utility

2Cited by
66References
9Claims
0Family size

Assignee

Inventors

Key dates

Filing dateApr 20, 2010
Grant dateDec 9, 2014
Priority date—
Expiry dateDec 9, 2031

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC07K2319/30
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

Disclosed are antibody fusion proteins with a modified FcRn binding site and nucleic acid molecules encoding them. The antibody fusion protein include two polypeptide chains, wherein the first polypeptide chain includes a biologically active molecule linked to at least a portion of an immunoglobulin constant region. The second polypeptide chain includes at least a portion of an immunoglobulin constant region. One of the polypeptide chains includes a mutation in the FcRn binding site that reduces binding to FcRn. Also disclosed are methods of producing the fusion proteins and methods of using the fusion proteins for treating diseases and conditions alleviated by the administration of the fusion proteins.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.